Biosimilars Market

The global biosimilars market was valued at USD 15.02 billion in 2020, growing at a CAGR of 21.54% during the forecast period from 2021 to 2026, in order to reach USD 48.00 billion by 2026. 

The escalating demand for biosimilars is primarily attributed to the rising burden of various chronic disorders such as diabetes, arthritis, and cancers, among others across the globe. Moreover, an increase in demand for cost-effective biosimilar drugs by the patients is also anticipated to boost the market for biosimilars. Also, patent expiry of successful and blockbuster biologics in the forthcoming years and increasing R&D investments and product launches, among others are further expected to augment the global biosimilars market.

Some of the key market players operating in the Biosimilars market include Pfizer Inc.  (NYSE: PFE), Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), Amgen, Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Novartis AG (SWX: NOVN), Bioeq AG, Fresenius SE & Co. KGaA (ETR: FRE), STADA Arzneimittel AG (STDAF), Gedeon Richter PLC (FRA: RIG2), Celltrion Healthcare Co., Ltd. (KOSDAQ: 091990), Samsung Bioepis. (Samsung Biologics) (KRX: 207940), Coherus BioSciences (NASDAQ: CHRS), Viatris Inc. (NASDAQ: VTRS), Shanghai Henlius Biotech, Inc. (HKG: 2696), Biocon Limited (BIOCON.NS), Biocad, mAbxience, Fujifilm Kyowa Kirin Biologics Co., Ltd., Alvotech, Sanofi (SNY), Senju Pharmaceutical Co., Ltd., and others.

DelveInsight’s “Biosimilars Market Insight & Forecast” report will offer an in-depth understanding of the Biosimilars market, further benefiting the competitors or stakeholders operating in the Biosimilars arena.

Biosimilars Overview

Biosimilar is a biological drug that is similar to, or nearly identical to, an existing FDA-approved reference biologic product. A biosimilar has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products.

Interested to know more about the functioning of Biosimilars- Visit @ Biosimilars Operations & Working.

Biosimilars Market Insights

Among all the regions, North America is expected to hold a major share in the overall biosimilars market during the forecasted period. This domination is owing to the rising burden of the population in the region suffering from various chronic disorders, and the presence of an effective reimbursement scenario for biosimilars in the region. Moreover, the presence of key market players such as Pfizer, Amgen, Eli Lilly, among others active in developing biosimilars is also expected to increase the market for biosimilars in the region.

For instance, in the US, as per the Crohn’s and Colitis Foundation 2018 data, approximately 1.6 and 3.1 million Americans suffer from Inflammatory Bowel Disease (IBD) in the same year. In addition, as per the stats revealed by the National Diabetes Statistics Report 2020, about 34.2 million Americans were suffering from diabetes in the same year. Therefore, the rising target population in the region is expected to bolster the demand for biosimilars thereby propelling the market for biosimilars in the country.

Also, in July 2018, the US FDA released the Biosimilars Action Plan to promote and enhance the development of biosimilars, potentially reducing the costs for patients and payors. Thus, such initiatives by the government organizations in the region will contribute to the market growth of biosimilars.

Furthermore, strategic business activities by the key players such as collaboration, acquisitions for market expansion, and product approvals & launches will also drive the Biosimilars market in the region.

For instance, on September 30, 2020, Shanghai Henlius Biotech, Inc. entered into a collaboration with Accord Healthcare Inc. (Accord US), according to which Henlius will grant an exclusive license to Accord US to develop and commercialize HLX02 (trastuzumab biosimilar in the United States of America and Canada. 

Also, on December 17, 2020, Amgen received the US FDA approval for RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA).

To read more about why North America is leading the market growth in the Biosimilars market, get a snapshot of the Biosimilars market report.

Biosimilars Market Dynamics

The market for biosimilars is gaining momentum at present owing to the growing cases of various chronic disorders such as autoimmune inflammatory disorders (Rheumatoid Arthritis, Inflammatory Bowel Diseases, and more), diabetes, cancer, and others among the worldwide population. For instance, according to the data published by the World Health Organization (WHO) in the year 2021, approximately 14 million people were suffering from rheumatoid arthritis in the world in 2019.

In addition, according to the statistics published by GLOBOCAN in the year 2020, a total of 19,292,789 new cases of cancer were reported worldwide in the same year. Thus, the rising burden of various chronic disorders is likely to surge the demand for biosimilars in the forthcoming years. Biologics are the key components of many therapeutic regimens in cancer treatment. However, the high cost of biologic-based drugs limits the accessibility of cancer treatment for many patients especially in developing countries where healthcare resources are limited. Biosimilars with biological activity comparable to their corresponding reference biologic drugs are often cost-effective and provide enhanced treatment accessibility for the target population.

Furthermore, the rise in patent expiry of various blockbuster biologics in the upcoming years is also expected to raise the market for biosimilars during the forecasted period. For instance, Avastin (Bevacizumab), a monoclonal antibody drug developed by Roche for the treatment of various cancers such as breast cancer, cervical cancer, colorectal cancer, and others lost its market exclusivity in the US in the year 2019 which opened the way for biosimilar players. For instance, in June 2019, Pfizer received the US FDA approval for its oncology biosimilar, ZIRABEV™ (BEVACIZUMAB-BVZR). Also, in July 2019, Amgen and Allergan plc (now a part of Abbvie Inc.) launched MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab) in the US market.

 Moreover, rising product approvals of the biosimilars are also anticipated to boost the market for biosimilars during the forecasted period. For instance, on September 17, 2021, FDA approved the Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) developed by Samsung Bioepis for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD).

Also, rising government initiatives and investments in educating prescribers, pharmacists, and consumers on the benefits of using biosimilar medicines will contribute to the biosimilars market growth.

Thus, all the aforementioned factors are expected to augment the global market for biosimilars during the forecasted period.

However, the high-cost involvement and complexities in manufacturing are likely to impede the biosimilars market.

Covid 19 Impact Analysis

The unprecedented COVID-19 pandemic has had a substantial impact on the biologics market. This is because the pandemic had imposed a great challenge on the pharmaceutical manufacturers focused on developing biosimilars. Moreover, the reduction in the approval of non-COVID drugs and therapeutics during the pandemic is projected to delay the product approval process as well as launches, thus stagnating the market growth. Also, the postponement of most of the clinical trials to minimize the infection transmission among the participants and to combat the pandemic situation led to the slow pace of research and development activities of the pipeline products. Furthermore, the implementation of logistical restrictions across the globe resulted in disruption in the supply chain of raw materials, and others which had an impact on biosimilar production. However, owing to the launch of vaccines and mass vaccination drive in different regions of the world, the biosimilar market is expected to regain normalcy in the post-pandemic period as all the facilities are expected to work normally.

To discuss the short/long-term impact of COVID-19, get a snapshot of the report Biosimilars market assessment.

Recent Breakthroughs in Biosimilars Market:

• In September 2021, Senju Pharmaceutical Co., Ltd. received approval for the marketing of the ophthalmic VEGF inhibitor “Ranibizumab BS intravitreal injection kit 10 mg/mL ‘Senju’” in Japan.
• In June 2021, Teva Pharmaceutical Industries Ltd. and Bioeq AG (“”Bioeq””) entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a biosimilar candidate to Lucentis® (ranibizumab) in Europe, Canada, Israel, and New Zealand.
• In March 2021, Cipla Limiteds’  subsidiary, Cipla Gulf expanded its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for the commercialization of patented biosimilars of the biologic medicine brands, Aflibercept (Eylea®), Ustekimumab (Stelara), Denosumab (Prolia, Xgeva®), and Golimumab (Simponi®) developed and manufactured by Alvotech.

Key Players Proactively Working In the Biosimilars Market

Key Biosimilars companies involved in manufacturing and production are making significant growth in the advancement of these devices. To boost their market position, they also engage in mergers and acquisitions. Some of the key Biosimilars companies operating actively in the Biosimilars market include Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Amgen, Inc., Eli Lilly and Company, Novartis AG, Bioeq AG, Fresenius SE & Co. KGaA, STADA Arzneimittel AG, Gedeon Richter PLC, Celltrion Healthcare Co., Ltd., Samsung Bioepis. (Samsung Biologics), Coherus BioSciences, Viatris Inc., Shanghai Henlius Biotech, Inc., Biocon Limited, Biocad, mAbxience, Fujifilm Kyowa Kirin Biologics Co., Ltd., Alvotech, Sanofi,  Senju Pharmaceutical Co., Ltd., and others.

Scope of the Biosimilars Market Report:

• Geography Covered: Global
• Study Period: 2022-2027
• Key Biosimilars Devices Companies: Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Amgen, Inc., Eli Lilly and Company, Novartis AG, Bioeq AG, Fresenius SE & Co. KGaA, STADA Arzneimittel AG, Gedeon Richter PLC, Celltrion Healthcare Co., Ltd., Samsung Bioepis. (Samsung Biologics), Coherus BioSciences, Viatris Inc., Shanghai Henlius Biotech, Inc., Biocon Limited, Biocad, mAbxience, Fujifilm Kyowa Kirin Biologics Co., Ltd., Alvotech, Sanofi,  Senju Pharmaceutical Co., Ltd., and others.
• Market Segmentation by Product Class: Monoclonal Antibodies, Recombinant Hormone/Proteins, Anti-Inflammatory Agents, Immunomodulators, And Others
• Market Segmentation By Manufacturing Type: In-House And Outsourced/Contract
• Market Segmentation by Application: Autoimmune Diseases, Blood Disorders, Oncology, Infectious Diseases, And Others
• Market Segmentation by Geography: North America, Europe, Asia-Pacific, Rest of the World (Middle East, Africa, and South America)
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/